Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Christophe Willekens, MD
Articles by Christophe Willekens, MD
Dr. Willekens Presents Efficacy Findings for Reduced-Dose Venetoclax in AML
Christophe Willekens, MD
Acute Myeloid Leukemia
|
July 16, 2024
Christophe Willekens, MD, compares standard dosing venetoclax for AML to seven-day dosing plus azacitidine.
View More